Temocapril

Temocapril
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 2-[(2S)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H28N2O5S2
Molar mass476.61 g·mol−1
3D model (JSmol)
  • CCOC(=O)[C@H](CCc1ccccc1)NC2CS[C@@H](CN(C2=O)CC(=O)O)c3cccs3
  • InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18?,20-/m0/s1
  • Key:FIQOFIRCTOWDOW-DXCJPMOASA-N
  (verify)

Temocapril (also known as temocaprilum [Latin]; brand name Acecol) is an ACE inhibitor. It was not approved for use in the US.

It is administered as inactive prodrug, then converted to its active metabolite, temocaprilat.

It was patented in 1984 and approved for medical use in 1994.

References

  1. ↑ Yasunari, K., Maeda, K., Nakamura, M., Watanabe, T., Yoshikawa, J., & Asada, A. (2004). Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile. Cardiovascular drug reviews, 22(3), 189–198. https://doi.org/10.1111/j.1527-3466.2004.tb00140.x
  2. ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 469. ISBN 9783527607495.